Focus: BriaCell Therapeutics is an oncology-focused immunotherapy biotech developing personalized cancer vaccines, primarily in breast cancer. The company is publicly traded but operates at pre-revenue stage with minimal cash reserves.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow BriaCell Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for BriaCell Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from BriaCell Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
BriaCell transfers cancer immunotherapy asset to BriaPro in USD$1.18 million deal - Mugglehead Investment Magazine
BriaCell transfers cancer immunotherapy asset to BriaPro in USD$1.18 million deal Mugglehead Investment Magazine
8-K Filing: BriaCell Therapeutics Corp. (BCTX, BCTXL, BCTXZ) (CIK 0001610820) — 8-K
8-K
If You Invested $1,000 in Briacell Therapeutics Corp (BCTX) - Stock Titan
If You Invested $1,000 in Briacell Therapeutics Corp (BCTX) Stock Titan
BCTX PE Ratio & Valuation, Is BCTX Overvalued - Intellectia AI
BCTX PE Ratio & Valuation, Is BCTX Overvalued Intellectia AI
BriaCell (NASDAQ: BCTX) boosts cash to fund cancer trials amid higher losses - Stock Titan
BriaCell (NASDAQ: BCTX) boosts cash to fund cancer trials amid higher losses Stock Titan
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting - Yahoo Finance
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting Yahoo Finance
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Asset divestiture and cash crisis indicate elevated restructuring risk; employment stability is compromised.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo